Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 19 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (3)
P 2 (6)
P 3 (2)
P 4 (1)

Trial Status

Unknown9
Recruiting4
Completed3
Withdrawn1
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT05024175Recruiting

Long-term Follow-up of Subjects Treated With CAR T Cells

NCT06826092Phase 2RecruitingPrimary

Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

NCT06527001Active Not RecruitingPrimary

Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer

NCT06215495Not ApplicableRecruiting

A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial

NCT05958849Phase 2UnknownPrimary

Advanced Pancreatic Cancer

NCT05897749Phase 4Unknown

Clinical Study on the Effect of Brucea Javanica Oil Emulsion Injection on the Survival of Patients With Advanced Colorectal Cancer Who Failed to Receive Multi-line Treatment

NCT05796700Not ApplicableCompleted

Microwave Ablation Versus Laparoscopic Hepatectomy for 3-5cm Hepatocellular Carcinoma

NCT03892577Unknown

Real-world Study for Patients With Advanced Hepatobiliary Tumors

NCT05310305Unknown

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

NCT05310357Unknown

Chromosomal Instability in Ovarian Cancer

NCT05310370Unknown

HRD and Resistance to PAPPi in EOC Patients

NCT04933669Phase 2RecruitingPrimary

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

NCT04664244Phase 2Unknown

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

NCT03342300Phase 2WithdrawnPrimary

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

NCT03359018Phase 2CompletedPrimary

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

NCT04127760Not ApplicableNot Yet Recruiting

Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection

NCT04101760Phase 3Unknown

Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer

NCT03742388Unknown

A Genomic Analysis of Evolution of Epithelia Ovarian Tumors

NCT00944918Phase 3CompletedPrimary

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Showing all 19 trials

Research Network

Activity Timeline